GRAN vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

GRAN

49.1
AI Score
VS
HIVE Wins

HIVE

55.9
AI Score

Investment Advisor Scores

GRAN

49score
Recommendation
HOLD

HIVE

56score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GRAN HIVE Winner
Revenue 1.81M 297.79M HIVE
Net Income -3.47M -148.45M GRAN
Gross Margin 88.6% -21.0% GRAN
Net Margin -192.2% -49.8% HIVE
ROE -47.9% -28.0% HIVE
ROA -26.7% -23.2% HIVE
Total Assets 13.03M 639.15M HIVE
Cash 1.45M 23.11M HIVE
Current Ratio 0.54 1.10 HIVE

Relative Price Performance (Last 90 Days)

GRAN 1M: +2.7% · 3M: +50.4% HIVE 1M: -13.5% · 3M: +12.5%

Current Technical Phase

GRAN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.4% over 20 days), RSI 53

RSI (14): 52.6 · Price: $1.50

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.4 · Price: $2.93

Fundamentals Snapshot

Metric GRAN HIVE
Market Cap
Forward P/E 0.0 -5.7
Trailing P/E
Revenue (TTM)
Revenue Growth -0.8% 1.3%
Gross Margin 0.7% 0.4%
Operating Margin -4.1% -0.8%
EPS -0.01 -0.66
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.